Xspray Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Xspray Pharma wird ein Gewinn- und Umsatzwachstum von 110.4% bzw. 99% pro Jahr prognostiziert, während der Gewinn pro Aktie um 110% pro Jahr wachsen soll.

Wichtige Informationen

110.4%

Wachstumsrate der Gewinne

110.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	46.9%
Wachstumsrate der Einnahmen	99.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OM:XSPRAY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,727	818	N/A	N/A	2
12/31/2025	614	-60	90	184	2
12/31/2024	131	-216	-382	-297	1
3/31/2024	N/A	-213	-257	-213	N/A
12/31/2023	N/A	-180	-256	-203	N/A
9/30/2023	N/A	-180	-268	-206	N/A
6/30/2023	N/A	-170	-242	-160	N/A
3/31/2023	N/A	-148	-223	-128	N/A
12/31/2022	N/A	-132	-238	-110	N/A
9/30/2022	N/A	-128	-216	-85	N/A
6/30/2022	N/A	-114	-198	-79	N/A
3/31/2022	N/A	-102	-185	-67	N/A
12/31/2021	N/A	-97	-148	-52	N/A
9/30/2021	N/A	-60	-146	-53	N/A
6/30/2021	N/A	-57	-145	-49	N/A
3/31/2021	N/A	-56	-141	-46	N/A
12/31/2020	N/A	-52	-141	-48	N/A
9/30/2020	N/A	-56	-141	-48	N/A
6/30/2020	N/A	-55	-140	-44	N/A
3/31/2020	N/A	-49	-135	-35	N/A
12/31/2019	N/A	-46	-126	-34	N/A
9/30/2019	-22	-41	-115	-29	N/A
6/30/2019	-14	-34	-97	-24	N/A
3/31/2019	-6	-30	-91	-27	N/A
12/31/2018	0	-23	-65	-18	N/A
9/30/2018	31	-17	-62	-25	N/A
6/30/2018	28	-16	-45	-12	N/A
3/31/2018	29	-8	-38	-7	N/A
12/31/2017	0	-14	N/A	-12	N/A
9/30/2017	35	1	N/A	12	N/A
6/30/2017	30	-3	N/A	-2	N/A
3/31/2017	21	-7	N/A	-6	N/A
12/31/2016	21	-4	N/A	-2	N/A
12/31/2015	5	-12	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: XSPRAY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1%).

Ertrag vs. Markt: XSPRAY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: XSPRAY wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: XSPRAYDie Einnahmen des Unternehmens (68.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: XSPRAYDie Einnahmen des Unternehmens (68.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von XSPRAY in 3 Jahren voraussichtlich hoch sein wird

Xspray Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 24% to kr91.50

Price target decreased by 11% to kr107

Price target decreased by 21% to kr106

Forecast to breakeven in 2024

Price target decreased to kr116

Forecast to breakeven in 2024

Recent updates

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127

Xspray Pharma Announces Results from Additional Bioequivalence Study

Xspray Pharma’S Hynap-Nilo Receives Fda Orphan Drug Designation for the Treatment of Chronic Myeloid Leukemia

New 90-day high: kr196

Xspray Pharma AB (publ) Decides to Await the Result of Two Ongoing Clinical Studies Before Submitting Its Anda Application

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Xspray Pharma AB (publ) to Report Q1, 2021 Results on May 06, 2021